RESUMEN
Pityriasis lichenoides is a rare inflammatory skin condition presenting with diffuse red-brown papules with evolution polymorphism and mica-like crust on older skin lesions. We present a 60-year-old female patient with pityriasis lichenoides chronica that manifested ten days after streptococcal pharyngitis. Initially, palpable purpura appeared on the lower extremities and later, erythematous-squamous papules and plaques appeared at the site of the palpable purpura and on the upper limbs and trunk. The patient had no history of hematological malignancy, viral hepatitis, kidney involvement, systemic rheumatic disease, or ANCA-associated vasculitis. After administration of methylprednisolone 20 mg for one month and an antimalarial agent (hydroxychloroquine 200 mg, 1 tablet bid) for three months, the skin lesions subsided without recurrence.
Asunto(s)
Pitiriasis Liquenoide , Púrpura , Infecciones Estreptocócicas , Humanos , Femenino , Persona de Mediana Edad , Pitiriasis Liquenoide/tratamiento farmacológico , Pitiriasis Liquenoide/patología , Infecciones Estreptocócicas/complicaciones , Infecciones Estreptocócicas/tratamiento farmacológico , Púrpura/etiología , Metilprednisolona/uso terapéutico , Hidroxicloroquina/uso terapéutico , Faringitis/tratamiento farmacológico , Faringitis/complicacionesAsunto(s)
Púrpura , Humanos , Púrpura/diagnóstico , Púrpura/patología , Púrpura/etiología , Pierna , Masculino , Diagnóstico Diferencial , FemeninoAsunto(s)
Dengue , Viaje , Humanos , Ecuador , Colombia , Dengue/diagnóstico , Masculino , Púrpura/etiología , Adulto , Enfermedades Transmisibles Importadas/diagnóstico , FemeninoAsunto(s)
Exantema , Púrpura , Humanos , Recién Nacido , Púrpura/etiología , Púrpura/diagnóstico , Exantema/etiología , Diagnóstico Diferencial , MasculinoAsunto(s)
Púrpura , Humanos , Femenino , Púrpura/diagnóstico , Persona de Mediana Edad , Trastornos de la Pigmentación/diagnóstico , PiernaRESUMEN
Laser hair removal (LHR) has been established as a safe and efficient method for eliminating unwanted hair. This study aimed to investigate the frequency of LHR complications and assess the contributing factors. During one year, 16,900 patients undergoing LHR therapy were evaluated for complications. For each case, two external controls were selected (matched based on age, sex, Fitzpatrick skin type (FST) III-IV, and the treated anatomical region). To assess the impact of anatomical region on complication occurrence, each patient was used as their internal control if another area was treated during the same session. GEE analysis was used for statistical analysis.The incidence of LHR complications was calculated to be 0.69%. The most common complications were petechia, purpura, and ecchymosis (31.66%) followed by pigmentation changes (20.0%). LHR complications were most commonly observed in the lower limbs (32.0%), face and neck (23.3%), and genitalia and thighs (22.3%), respectively. Possible risk factors were younger age (OR = 0.74, P-value ≤ 0.001), operating LHR in the head and neck (OR = 5.8, P-value = 0.022), utilization of the alexandrite laser (OR = 2.32, P-value = 0.011), and fluence in the Alexandrite laser (OR = 3.47, P-value = 0.003).Overall, the results of this study indicate that LHR is generally a safe method for removing unwanted hair. However, factors such as younger age, treatment of the facial area, and use of the alexandrite laser especially with higher fluence levels in patients with FST III-IV were identified as potential risk factors.
Asunto(s)
Remoción del Cabello , Láseres de Estado Sólido , Humanos , Remoción del Cabello/efectos adversos , Remoción del Cabello/métodos , Femenino , Estudios de Casos y Controles , Masculino , Adulto , Factores de Riesgo , Persona de Mediana Edad , Láseres de Estado Sólido/efectos adversos , Láseres de Estado Sólido/uso terapéutico , Adulto Joven , Equimosis/etiología , Equimosis/epidemiología , Centros de Atención Terciaria , Púrpura/etiología , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/epidemiología , Adolescente , Terapia por Láser/efectos adversos , Terapia por Láser/métodosRESUMEN
A unique dermatopathology incident arose after administration of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine. Specifically, a transient purpuric interface dermatitis occurred 5 days post-second vaccine with the presentation of erythematous papules with erythema multiforme-type findings. A patient developed purpuric interface dermatitis with micro-vesiculation post-vaccination which ultimately resolved without sequelae.
Asunto(s)
Vacunas contra la COVID-19 , Eritema Multiforme , Humanos , Eritema Multiforme/inducido químicamente , Eritema Multiforme/patología , Vacunas contra la COVID-19/efectos adversos , Vacuna nCoV-2019 mRNA-1273/efectos adversos , Femenino , Erupciones por Medicamentos/etiología , Erupciones por Medicamentos/patología , Masculino , COVID-19/prevención & control , Persona de Mediana Edad , Púrpura/etiología , Púrpura/patologíaRESUMEN
BACKGROUND Post-transfusion purpura (PTP) is a rare delayed adverse event characterized by severe thrombocytopenia associated with mucosal bleeding and purpura. PTP is associated with the development of alloantibodies to human platelet antigens (HPAs) and should be distinguished from other thrombocytopenic syndromes. This report is of a 69-year-old man with refractory cardiogenic shock and thrombocytopenia 4 days following blood transfusion, diagnosed with post-transfusion purpura. CASE REPORT A 69-year-old man was admitted to a tertiary medical center with refractory cardiogenic shock. Four days after he received 1 unit of packed red blood cells, his platelet count plummeted from 147 K/uL to <2 K/uL within hours, associated with delayed presentation of notable hematuria and femoral catheter oozing. An extensive thrombocytopenia work-up, including an initial platelet antibody screen, was unrevealing. The patient was treated with supportive transfusions, dexamethasone, and intravenous immunoglobulin, with rapid platelet recovery. Post-transfusion purpura panel testing later identified anti-human platelet antigen-5b antibodies, confirming the diagnosis. CONCLUSIONS This report presents an unusual course and presentation of post-transfusion purpura in an elderly man. Unusual features of this case include male sex, hyper-acuity of thrombocytopenia, lack of prior transfusions, exam findings, identification of a less common alloantibody, and negative initial platelet antigen screening. This report highlights the importance of monitoring patients for post-transfusion adverse events. Although PTP is rare, rapid diagnosis and management are required to control this potentially life-threatening condition.
Asunto(s)
Isoanticuerpos , Humanos , Masculino , Anciano , Isoanticuerpos/inmunología , Reacción a la Transfusión/diagnóstico , Reacción a la Transfusión/inmunología , Púrpura/etiología , Choque Cardiogénico/etiología , Transfusión de Eritrocitos/efectos adversosAsunto(s)
Gastroscopía , Púrpura , Humanos , Gastroscopía/métodos , Gastroscopía/efectos adversos , Púrpura/etiología , Masculino , FemeninoRESUMEN
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA), is a rare ANCA-associated systemic vasculitis. Its overlapping features with other vasculitic or eosinophilic diseases, and the wide and heterogeneous range of clinical manifestations, often result in a delay to diagnosis. OBJECTIVE: To identify red flags that raise a suspicion of EGPA to prompt diagnostic testing and to present an evidence-based clinical checklist tool for use in routine clinical practice. METHODS: Systematic literature review and expert consensus to identify a list of red flags based on clinical judgement. GRADE applied to generate a strength of recommendation for each red flag and to develop a checklist tool. RESULTS: 86 studies were included. 40 red flags were identified as relevant to raise a suspicion of EGPA and assessed by the experts as being clinically significant. Experts agreed that a diagnosis of EGPA should be considered in a patient aged ≥6 years with a blood eosinophil level >1000 cells/µL if untreated and >500 cells/µL if previously treated with any medication likely to have altered the blood eosinophil count. The presence of asthma and/or nasal polyposis should reinforce a suspicion of EGPA. Red flags of asthma, lung infiltrates, pericarditis, cardiomyopathy, polyneuropathy, biopsy with inflammatory eosinophilic infiltrates, palpable purpura, digital ischaemia and ANCA positivity, usually anti-myeloperoxidase, among others, were identified. CONCLUSION: The identification of a comprehensive set of red flags could be used to raise a suspicion of EGPA in patients with eosinophilia, providing clinicians with an evidence-based checklist tool that can be integrated into their practice.
Asunto(s)
Anticuerpos Anticitoplasma de Neutrófilos , Granulomatosis con Poliangitis , Humanos , Granulomatosis con Poliangitis/diagnóstico , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Síndrome de Churg-Strauss/diagnóstico , Asma/diagnóstico , Eosinófilos , Pericarditis/diagnóstico , Lista de Verificación , Eosinofilia/diagnóstico , Pólipos Nasales/diagnóstico , Púrpura , Recuento de LeucocitosRESUMEN
BACKGROUND Pigmented purpuric dermatosis (PPD) is a rare disease that is poorly understood but thought to result from inflammation of the capillaries causing extravasation of erythrocytes into the soft tissue. There are a variety of potential causes, including medications, such as acetaminophen and aspirin, abnormal humoral immunity, and excessive exercise. Although benign, PPD can be bothersome to patients due to associated pruritus, weeping, and poor cosmetic results. Treatment of this lesion is difficult, with no standardized regimen and a tendency for relapse once treatment is discontinued. CASE REPORT This case reports on a 77-year-old man who presented to an outpatient dermatology clinic with bilateral lower extremity edema with associated weeping and erythema for 1 year. A biopsy was conducted and resulted as PPD. He began treatment with excimer laser therapy after conservative and topical treatment options failed, with resolution of symptoms without recurrence for approximately 1 year. CONCLUSIONS PPD is notoriously difficult to treat, and historic treatment options include topical corticosteroids, oral supplements, and immunomodulators, all of which come with a range of adverse effects. However, new literature supports the use of phototherapy to treat PPD, with varying results. Previously implemented options include but are not limited to phototherapy with psoralen plus ultraviolet A, narrow band ultraviolet B, advanced fluorescence technology pulsed light, and fractional non-ablative 1540-nm erbium: glass laser, each with varying degrees of success. This case discusses the successful treatment of recalcitrant PPD with excimer laser therapy and maintenance of remission for approximately 1 year.